CY1107236T1 - Παραγωγα της 2-αμινο-3-(αλκυλο)-πυριμιδονης ως gsk3. βητα αναστολεις - Google Patents

Παραγωγα της 2-αμινο-3-(αλκυλο)-πυριμιδονης ως gsk3. βητα αναστολεις

Info

Publication number
CY1107236T1
CY1107236T1 CY20081100270T CY081100270T CY1107236T1 CY 1107236 T1 CY1107236 T1 CY 1107236T1 CY 20081100270 T CY20081100270 T CY 20081100270T CY 081100270 T CY081100270 T CY 081100270T CY 1107236 T1 CY1107236 T1 CY 1107236T1
Authority
CY
Cyprus
Prior art keywords
gsk3
amino
alkyl
beta blockers
pyrimidone derivatives
Prior art date
Application number
CY20081100270T
Other languages
English (en)
Inventor
Antonio Almario Garcia
Ryoichi Ando
Keiichi Aritomo
Jonathan Reid Frost
Adrien Tak Li
Aya Shoda
Fumiaki Uehara
Kazutoshi Watanabe
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of CY1107236T1 publication Critical patent/CY1107236T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Ένα παράγωγο πυριμιδόνης το οποίο αντιπροσωπεύει ο τύπος (Ι) ή ένα άλας του,
CY20081100270T 2000-03-23 2008-03-07 Παραγωγα της 2-αμινο-3-(αλκυλο)-πυριμιδονης ως gsk3. βητα αναστολεις CY1107236T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00400800A EP1136482A1 (en) 2000-03-23 2000-03-23 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
PCT/EP2001/003640 WO2001070729A1 (en) 2000-03-23 2001-03-22 2-amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors
EP01959921A EP1276738B8 (en) 2000-03-23 2001-03-22 2-amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors

Publications (1)

Publication Number Publication Date
CY1107236T1 true CY1107236T1 (el) 2012-05-23

Family

ID=8173604

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100270T CY1107236T1 (el) 2000-03-23 2008-03-07 Παραγωγα της 2-αμινο-3-(αλκυλο)-πυριμιδονης ως gsk3. βητα αναστολεις

Country Status (16)

Country Link
US (2) US6844335B2 (el)
EP (2) EP1136482A1 (el)
JP (1) JP4778657B2 (el)
KR (1) KR100820543B1 (el)
CN (2) CN1247567C (el)
AR (1) AR028280A1 (el)
AT (1) ATE380806T1 (el)
AU (1) AU2001281487A1 (el)
CA (1) CA2401241C (el)
CY (1) CY1107236T1 (el)
DE (1) DE60131844T2 (el)
DK (1) DK1276738T3 (el)
ES (1) ES2296783T3 (el)
PT (1) PT1276738E (el)
SI (1) SI1276738T1 (el)
WO (1) WO2001070729A1 (el)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR023052A1 (es) 1998-09-25 2002-09-04 Mitsuharu Yoshimura Milton Derivados de pirimidona
EP1136482A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
SE518184C2 (sv) 2000-03-31 2002-09-03 Perstorp Flooring Ab Golvbeläggningsmaterial innefattande skivformiga golvelement vilka sammanfogas med hjälp av sammankopplingsorgan
WO2001080893A1 (fr) 2000-04-26 2001-11-01 Eisai Co., Ltd. Compositions medicinales favorisant les mouvements intestinaux
EP1427709B1 (en) 2001-09-21 2005-12-14 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
SI1427720T1 (sl) * 2001-09-21 2009-08-31 Mitsubishi Tanabe Pharma Corp 3-substituirani-4-pirimidonski derivati
TWI335221B (en) * 2001-09-27 2011-01-01 Alcon Inc Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
TWI301834B (en) 2001-10-22 2008-10-11 Eisai R&D Man Co Ltd Pyrimidone compound and pharmaceutical composition including the same
TWI330183B (el) 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
JP4616003B2 (ja) 2002-12-16 2011-01-19 田辺三菱製薬株式会社 ３−置換−４−ピリミドン誘導体
EP1460075A1 (en) * 2003-03-21 2004-09-22 Sanofi-Synthelabo Substituted 8-Pyridinyl-6,7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 8-Phenyl-6-7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one derivatives
EP1460076A1 (en) * 2003-03-21 2004-09-22 Sanofi-Synthelabo Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
CN1894234A (zh) 2003-03-25 2007-01-10 武田药品工业株式会社 二肽基肽酶抑制剂
TWI357408B (en) * 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives
KR20060041309A (ko) 2003-08-13 2006-05-11 다케다 야쿠힌 고교 가부시키가이샤 ４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
EP1699777B1 (en) 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1713793A4 (en) * 2004-02-04 2009-09-02 Smithkline Beecham Corp PYRIMIDINONE COMPOUNDS SUITED AS KINASEINHIBITORS
CN102134231B (zh) 2004-03-15 2020-08-04 武田药品工业株式会社 二肽基肽酶抑制剂
CN1980681A (zh) * 2004-07-09 2007-06-13 新加坡科技研究局 GSK－3β的调节及治疗增殖性病变的方法
AR050865A1 (es) 2004-09-09 2006-11-29 Sanofi Aventis Derivados de 2- morfolino-4-pirimidona
CA2581179A1 (en) * 2004-09-29 2006-04-06 Mitsubishi Pharma Corporation 6-(pyridinyl)-4 pyrimidone derivatives as tau protein kinase 1 inhibitors
EP1828192B1 (en) 2004-12-21 2014-12-03 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2006117212A2 (en) 2005-05-04 2006-11-09 Develogen Aktiengesellschaft Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
ME02005B (me) 2005-09-14 2012-08-31 Takeda Pharmaceuticals Co Inhibitori dipeptidil peptidaze za lečenje dijabetesa
EP1924567B1 (en) 2005-09-16 2012-08-22 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
TW200813015A (en) * 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
MX2009001913A (es) * 2006-08-23 2009-03-06 Pfizer Prod Inc Compuestos de pirimidona como inhibidores de gsk-3.
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
AR076014A1 (es) * 2009-04-02 2011-05-11 Sanofi Aventis Derivados de 3- (1,4) oxazepan -4-pirimidona
EP2464632A1 (en) 2009-08-13 2012-06-20 Mitsubishi Tanabe Pharma Corporation Pyrimidone derivatives used as tau protein kinase 1 inhibitors
US8940738B2 (en) 2009-08-13 2015-01-27 Mitsubishi Tanabe Pharma Corporation Pyrimidone compounds
US20170209488A1 (en) 2014-07-17 2017-07-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for treating neuromuscular junction-related diseases
WO2016207366A1 (en) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of viral infections
US11331313B2 (en) 2017-05-22 2022-05-17 Whitehead Institute For Biomedical Research KCC2 expression enhancing compounds and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4935631B1 (el) 1970-12-28 1974-09-25
JPS4935633B1 (el) 1970-12-30 1974-09-25
JPS559099B2 (el) * 1972-08-07 1980-03-07
JPS4935633A (el) 1972-08-09 1974-04-02
US4460589A (en) * 1980-10-03 1984-07-17 The Upjohn Company Process for treating hypertension
TW229142B (el) * 1992-04-15 1994-09-01 Nissan Detrochem Corp
WO1998016528A1 (en) * 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
EP0948496A2 (en) * 1996-12-05 1999-10-13 Amgen inc. Substituted pyrimidinone and pyridone compounds and methods of use
WO1998024782A2 (en) * 1996-12-05 1998-06-11 Amgen Inc. Substituted pyrimidine compounds and their use
AR023052A1 (es) * 1998-09-25 2002-09-04 Mitsuharu Yoshimura Milton Derivados de pirimidona
EP1136482A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors

Also Published As

Publication number Publication date
US7378413B2 (en) 2008-05-27
US20050130998A1 (en) 2005-06-16
CN1891220A (zh) 2007-01-10
CN1419552A (zh) 2003-05-21
CA2401241A1 (en) 2001-09-27
KR100820543B1 (ko) 2008-04-07
JP2003528095A (ja) 2003-09-24
AR028280A1 (es) 2003-04-30
ES2296783T3 (es) 2008-05-01
SI1276738T1 (sl) 2008-06-30
DK1276738T3 (da) 2008-04-21
EP1136482A1 (en) 2001-09-26
EP1276738B1 (en) 2007-12-12
KR20020093848A (ko) 2002-12-16
WO2001070729A1 (en) 2001-09-27
ATE380806T1 (de) 2007-12-15
US6844335B2 (en) 2005-01-18
PT1276738E (pt) 2008-02-28
AU2001281487A1 (en) 2001-10-03
CN1247567C (zh) 2006-03-29
DE60131844T2 (de) 2008-11-27
DE60131844D1 (de) 2008-01-24
US20030187004A1 (en) 2003-10-02
EP1276738B8 (en) 2008-02-20
CA2401241C (en) 2011-11-29
JP4778657B2 (ja) 2011-09-21
EP1276738A1 (en) 2003-01-22

Similar Documents

Publication Publication Date Title
CY1107236T1 (el) Παραγωγα της 2-αμινο-3-(αλκυλο)-πυριμιδονης ως gsk3. βητα αναστολεις
CY1111125T1 (el) Υποκατεστημενα παραγωγα δικυκλικης πυριμιδονης
CY1110064T1 (el) Παραγωγα φαινυλ-πιπεραζινης ως αναστολεις επαναπροσληψης σεροτονινης
RS53599B1 (en) PIRIDON DERIVATIVES FOR STRESS MODULATION OF ACTIVATED PROTEIN KINASE SYSTEMS
DK1633697T3 (da) Fremgangsmåde til fremstilling af substituerede 3-aryl-butyl-aminforbindelser
HRP20080664A2 (en) Substituted pyridine herbicides
CY1110489T1 (el) Παραγωγα ισοκινολινης
DK1483265T3 (da) Purinderivater som kinaseinhibitorer
NO20061317L (no) Imidazopyridinderivater som induserbare NO-syntaseinhibatorer
DE122010000035I2 (de) Substituierte thien-3-yl-sulfonylamino(thio)carbonyl-triazolin(thi)one
CY1106716T1 (el) 4-υποκαθισταμενα παραγωγα πιπεριδινης
TR200402779T4 (tr) Benzotiyofen türevi bileşikler, bunların hazırlama yöntemleri ve kullanımları.
EA200801365A1 (ru) Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины
NO20061316L (no) Imidazopyndinderivater som induserbare NO-syntaseinhibitorer
NO20061344L (no) Imidazopyridinderivater som induserbare NO-syntaseoinhibitorer
SV2003000981A (es) Fenil-heterociclil-eteres ref. pcs10973
DE69917000D1 (de) Butorphanol enthaltende formulierungen mit verzögerter freisetzung
NO20023001D0 (no) Substituerte piperazinderivater som MTP inhibitorer
DK1347984T3 (da) Fremgangsmåde til fremstilling af taxanderivater
DK1255745T3 (da) Syntese af vandoplöseligt 9-dihydro-paclitaxel afledninger fra 9-dihydro-13-acetylbaccatin III
CO5540381A2 (es) Derivados de imidazotriacinonas y su uso contra procesos inflamatorios y/o enfermedades inmunitarias
DE60106606D1 (de) Substituierte stilbenverbindungen als glucoseaufnahme inhibitoren
ATE440844T1 (de) Substituierte 2- (diazabicycloalkyl)pyrimidonderivate
DK1349850T3 (da) Natriumkanalmodulatorer, der er afledt af 2-piperidylimidazoler
ECSP055538A (es) Cefalosporina